BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 30
• 31

• Drug Development

  Novavax Showcases Data from Expanding Vaccine Portfolio at IDWeek 2022

  Novavax, Inc. (Nasdaq: NVAX) will present new data from the Phase 3 PREVENT-19 trial evaluating its protein-based COVID-19 vaccine (NVX-CoV2373) as a booster in adults, including a breakdown by age and by booster dose interval (8 and 11 months) at IDWeek 2022, October 20 to 22, 2022.

  October 20, 2022

   · 

  6 min read
• BioMidwest

  Cingulate to Present at LD Micro Investor Conference

  Cingulate Inc. (NASDAQ: CING) today announced that Cingulate Chairman & CEO Shane J. Schaffer will present at the LD Micro Main Event XV investor conference on October 26, 2022.

  October 20, 2022

   · 

  1 min read
• BioCapital

  ABL Awarded NIH Contract for Continued Support of HIV Vaccine Development

  Advanced BioScience Laboratories announced it has been awarded a contract for “Preclinical and translational vaccine development for HIV and other candidate agents” by the Division of AIDS within the National Institute of Allergy and Infectious Disease of the National Institutes of Health.

  October 20, 2022

   · 

  3 min read
• Cell Separation Market Size to Hit USD 30.8 Billion by 2030

  According to Nova one advisor, the global Cell Separation market size is expected to hit around USD 30.8 billion by 2030 from valued at USD 7.6 billion in 2021 and growing at a CAGR of 19.8% from 2022 to 2030

  October 20, 2022

   · 

  9 min read
• 3D Cell Culture Market Size to Hit USD 6.8 Billion by 2030

  According to Nova one advisor, the global 3D Cell Culture market size is expected to hit around USD 6.8 billion by 2030 from valued at USD 2.9 billion in 2021 and growing at a CAGR of 11.40% from 2022 to 2030

  October 20, 2022

   · 

  5 min read
• Business

  AVITA Medical to Announce Third Quarter 2022 Financial Results

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) announced today that it will report its third quarter 2022 financial results after the close of the U.S. financial markets on Thursday, November 10, 2022.

  October 20, 2022

   · 

  3 min read
• Drug Development

  Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate

  Immunic, Inc. (Nasdaq: IMUX) today announced the outcome of a pre-planned interim group-level data analysis of its phase 1b clinical trial of IMU-935 in patients with moderate-to-severe psoriasis.

  October 20, 2022

   · 

  9 min read
• Business

  Karyopharm to Report Third Quarter 2022 Financial Results on November 3, 2022

  Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report third quarter 2022 financial results on Thursday, November 3, 2022.

  October 20, 2022

   · 

  2 min read
• Business

  Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022

  Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2022 financial results on Wednesday, November 2, 2022, after the close of the U.S. financial markets.

  October 20, 2022

   · 

  2 min read
• Business

  Vicarious Surgical Announces Changes to Board of Directors

  Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) today announced the resignation of technology-focused venture capitalists Dror Berman and Samir Kaul from the Vicarious Surgical Board of Directors effective October 18, 2022.

  October 20, 2022

   · 

  6 min read